N. Nguyen

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

S. Grant, M. Muschen, Yun Dai, 2011, Clinical Cancer Research.

Cancer Therapy : Preclinical HDAC Inhibitors Potentiate the Activity of the BCR / ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or-Resistant BCR / ABL þ Leukemia Cells In Vitro and In Vivo

S. Grant, M. Muschen, Yun Dai, 2011 .